Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Merck USA (MSD) acquires Phase 2 biotech for US$ 10.8 Bln.

<< Previous

Bullboard Posts

Next >>

Comment by KTDfyion Apr 23, 2023 1:04pm

129 Views

Post# 35409393

RE:RE:RE:RE:RE:RE:RE:RE:Merck USA (MSD) acquires Phase 2 biotech for US$ 10.8 Bln.

Pelareorep works synergistic with CI. It works better in some than others. They knew this, thus the forwarding into Roche's CI. As the CIs develop, there's going to be a need to understand how pela works with that particular CI. AWARE study answered questions that needed to be answered as in MOA. These synergies will have to be explored further. That said, the current trials are meant for a successful entry into phase 3. With that established BP is going to run with it. They have the resources to explore without the financial restraints of oncy the company. Make sense.

<< Previous

Bullboard Posts

Next >>

POET increases production capacity to meet AI demand